The global progressive pulmonary fibrosis (PPF) Treatment market is expected to reach at USD 3.72 Million in 2023 and is projected to exhibit a CAGR of 7.5% from 2023 to 2033.
Several experimental cancer drugs show promise in treating idiopathic pulmonary fibrosis as a potential treatment in the future. Also, key players are increasingly focusing on research and development activity, which will create lucrative growth opportunities in the progressive pulmonary fibrosis (PPF) treatment market.
As the field of image analysis and processing advances, machine learning applications based on deep learning provide new possibilities for the use of radio mics and deep learning in image analysis. It is imperative to develop optimized algorithms in collaboration with appropriate predictors of disease outcomes and to validate radiological biomarkers against those predictors.
In randomized clinical trials, antifibrotic drugs, either nintedanib or pirfenidone, slow the progression of progressive ILD associated with IPF or progressive non-IPF ILD. The clinical management of this subgroup of patients in its current state is beginning to see a new era that offers the perfect opportunity to explore still unexplored territories within the industry.
| Data Points | Key Statistics |
|---|---|
| Estimated Base Year Value (2022) | USD 3.5 Million |
| Expected Market Value (2023) | USD 3.72 Million |
| Anticipated Forecast Value (2033) | USD 7.7 Million |
| Projected Growth Rate (2023 to 2033) | 7.5% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to a report from Future Market Insights (FMI). From 2018 to 2022, sales witnessed significant growth, registering a CAGR of 6.3%. Current treatments can prolong the life of pulmonary fibrosis patients by nearly two or five years. Many researchers are currently working to discover the cause and potential treatments for pulmonary fibrosis in developed countries. Innovative therapeutic pathways for pulmonary fibrosis are currently being developed by academic institutions, pharmaceutical firms, and biopharmaceutical companies.
A rise in the number of patients with progressive pulmonary fibrosis (PPF) and the awareness surrounding its treatment is also expected to spur the development of more PPF-related pharmaceutical drugs. The progressive pulmonary fibrosis (PPF) treatment market is expected to grow at a moderate rate due to the complicated reimbursement associated with multiple patent expirations. Researchers around the world are exploring ways to treat the side effects of PPF treatments.
A new study has shown that saracatinib may be effective in treating idiopathic pulmonary fibrosis (IPF). According to a study published in the American Journal of Respiratory and Critical Care Medicine, Saracatinib reduced tissue scarring in preclinical models of IPF similarly to two drugs in clinical trials. Researchers from National Jewish Health, Mount Sinai Ichan School of Medicine, Yale School of Medicine, and AstraZeneca investigated the effectiveness of oral therapy treatments using a novel computational approach. The global demand for progressive pulmonary fibrosis (PPF) treatment is projected to increase at a CAGR of 7.5% during the forecast period between 2023 and 2033, reaching a total of USD 7.7 Million in 2033.
Drug Approvals and New Therapies are Expected to Grow the Market
Manufacturers of pulmonary fibrosis drugs are focusing on building strong pipelines for future launches with better patient compliance. Novel therapies are being developed for pulmonary fibrosis by different manufacturers.
According to researchers, pulmonary fibrosis treatment may be accomplished with the launch of some large molecules in the upcoming years. Various research activities and drug approval processes are being conducted by manufacturers of pulmonary fibrosis drugs in various regions to generate revenue.
Technological advances and advances in medical science have led to the development of new and innovative treatments. In addition, this has contributed to the growth of the global market for pulmonary fibrosis treatments. As a result of the high prevalence of pulmonary fibrosis, several institutions have been studying the disease to understand its causes and thus contributed to the growth of the market.
Principal Consultant
Progression therapy for pulmonary fibrosis has promising growth prospects in the future. New hope has been provided for patients suffering from pulmonary fibrosis due to recent breakthroughs in the field. In addition, new medications are being developed, stem cells are being used, new surgical techniques are being developed, and gene therapy is being utilized.
Pneumofibrosis patients can benefit from the development of new medications. A study found that pirfenidone slowed the progression of the condition and improved the overall quality of life of patients. Additionally, biologics have been found to be effective in the treatment of pulmonary fibrosis. Among the many promising treatments for pulmonary fibrosis, stem cell therapy is one of the most promising.
The stem cells in the lungs are capable of regenerating tissue, and they can be used to replace damaged tissue. By doing so, oxygenation can be improved and complications can be reduced. There have been promising results in stem cell therapy so far, even though the field is still in its infancy.
MicroRNAs are considered potential targets for treating progressive pulmonary fibrosis in the future. MiRNAs play a key role in regulating different cellular functions, making it essential to understand how they influence inflammatory events causing pulmonary fibrosis to occur. Several clinical and laboratory biomarkers are being investigated in order to form a prediction of which subgroup of patients is most likely to progress or develop lung fibrosis in order to achieve a more accurate prediction.
Insufficient Treatment Options and Associated Disorders Restrict Treatment Options
Managing pulmonary fibrosis presents a limited range of treatment options. In the past, immunosuppressive medications like corticosteroids were commonly used to treat diseases off-label. As a result, Boehringer Ingelheim Pharmaceuticals, Inc. and Genentech introduced Ofev (nintedanib) and Esbriet (pirfenidone), two medications that revolutionized the treatment of pulmonary fibrosis worldwide.
One of the major barriers to the development of treatments for pulmonary fibrosis is the high price of drugs and low per capita spending on the treatment, as well as the inaccessibility of drugs such as Ofev and Esbriet. Poor and middle-income countries are often subject to a delayed diagnosis, which can lead to more comorbidities and complicate illness management. Over 60% of pulmonary fibrosis patients suffer from comorbidities including pulmonary hypertension.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Increasing Treatment Adoption for Progressive Pulmonary Fibrosis (PPF) with New Drug Development
Due to its well-established healthcare system and high awareness of asthma patients, North America is predicted to hold 51% of the global healthcare market by 2023. Currently, North America dominates the market for progressive pulmonary fibrosis treatment. During the forecast period of 2023 to 2033, the region will continue to be a strong contributor.
The persistently increasing number of pulmonary fibrosis patients is driving the North American market for pulmonary fibrosis treatments. Asthma is one of many respiratory diseases that are on the rise in the region at a high rate of prevalence, and those cases are on the rise at an alarming rate. With such a large number of patients in the region, it is expected that the pulmonary fibrosis treatment market will thrive in the near future. In addition, rapidly evolving healthcare infrastructure, along with a growing health awareness in North America, are driving the growth of pulmonary fibrosis treatments.
A new generation of drugs being developed and approved by the FDA in this region is expected to flourish in the market further. For instance, there are two drugs approved by the Food and Drug Administration (FDA) at the moment for treating the most common form of PF, which is known as idiopathic pulmonary fibrosis (IPF). Ofev® and Esbriet® both contain nintedanib (Ofev®). Clinical trials have shown that these drugs slow down lung scarring and fibrosis, so they're called anti-fibrotic agents. Mild, moderate, and severe forms of IPF can be treated with these drugs.
Progressive Pulmonary Fibrosis Treatment Demand Grows as Research and Medical Facilities Expand
With a market share of 35% during the forecast period, Europe will dominate the global progressive pulmonary fibrosis (PPF) Treatment market. Research and development activities are growing rapidly in the region, and government grants are being awarded to encourage more such studies. This is expected to lead to promising growth in the pulmonary fibrosis treatment market.
Approximately 29.2% of the European market was dominated by Germany in 2022. A growing geriatric population in Germany continues to drive adoption rates higher. A growing geriatric population, Industrial advancements, and an increase in Research and Development spending all contribute to Germany's progressive pulmonary fibrosis treatment market. Increasing age is associated with a higher risk of pulmonary-related problems that occur in the body. Increasing geriatric populations are a major factor driving demand for pulmonary fibrosis treatment.
Further growth of the market is expected to be driven by the increase in hospitals for the treatment of pulmonary fibrosis and advancements in healthcare technologies and tools. More than 150 clinics in Europe are represented by the German Medical Group. Medical services can be obtained at leading German clinics through the company.
An increasing Number of Cancer Patients Will Increase Growth at a Significant Rate
Based on the drug class of progressive pulmonary fibrosis (PPF) treatment the market for MAPK inhibitors is expected to grow the market. As the prevalence of cancer rises, the demand for MAPK inhibitors is expected to increase thereby boosting the growth of the market. Pharmaceutical therapeutic targets for pituitary adenomas are also increasing due to the growth in healthcare expenditures. Increasing government funding will also help improve the healthcare infrastructure, further impacting the market dynamics.
In addition to the studies that have been conducted, there has been evidence that the signaling pathway plays a significant role in various types of cancers, such as melanoma and non-small cell lung cancer. As a result, researchers are increasingly interested in targeting the MAPK signaling pathway as a potentially effective cancer treatment option. Researchers and developers have been working on developing MEK inhibitors that inhibit MAPK signaling in this sector. This will all contribute to the growth of the MAPK inhibitor market.
Treatment of Progressive Pulmonary Fibrosis (PPF) to Gain Traction in Retail Pharmacies
Based on distribution channels, the global market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies. The revenue share of retail pharmacies of PPF is expected to accumulate a revenue share of 52.6% during the forecast period.
Currently, prescription drug formulations are easily obtainable and over-the-counter drugs are available at retail pharmacies, driving the market for pulmonary fibrosis treatment. With more in-house pharmacies partnering with outer retail outlets, drug sales have grown in the market. Memberships are growing, and discounts are available for loyal customers which has added further momentum to market growth. Future retail stores that deliver drugs to homes in the locality and accept online drug orders are expected to expand.
Some of the start-ups in the progressive pulmonary fibrosis (PPF) treatment market include-
Strategic partnerships can boost revenue and market share for manufacturers by increasing production and meeting consumer demand. End users will benefit from the use of new products and technologies by promoting them. Strategic partnerships can be formed by companies in order to increase their production capacity.
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 3.72 Million |
| Market Value in 2033 | USD 7.7 Million |
| Growth Rate | CAGR 7.5% |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Drug Class, Treatment, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Germany, United Kingdom, France, Spain, Italy, India, Malaysia, Singapore, Thailand, China, Japan, South Korea, Australia, New Zealand, GCC Countries, South Africa, Israel |
| Key Companies Profiled | Boehringer Ingelheim; Bristol-Myers Squibb; FibroGen; Hoffmann-La Roche Ltd; Pliant Therapeutics, Inc.; United Therapeutics Corporation; Galapagos; Novartis AG; Prometic Life Sciences Inc.; Merck & Co., Inc. |
| Customization | Available Upon Request |
Through 2033, the market is anticipated to prosper at a 7.5% CAGR.
By 2033, the market is anticipated to be worth about USD 7.7 million.
The market is anticipated to clock in at USD 3.72 million in 2023.
With 29.2% of the total market, Germany took over the Europe market.
North America is anticipated to possess 51% of the market by 2023.
Based on the distribution channels, PPF's retail pharmacies acquired a revenue share of 52.6%.
1. Executive Summary 2. Market Overview 3. Market Background 4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class 5.1. MAPK Inhibitors 5.2. Tyrosine Inhibitors 5.3. Autotaxin Inhibitors 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Hospital Pharmacies 6.2. Retail Pharmacies 6.3. Online Pharmacies 7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment 7.1. Self-care 7.2. Medicines 7.2.1. Pirfenidone 7.2.2. Nintedanib 7.2.3. Others 7.3. Lung transplant 7.4. Palliative Care 8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 8.1. North America 8.2. Latin America 8.3. Europe 8.4. South Asia 8.5. East Asia 8.6. Oceania 8.7. Middle East and Africa (MEA) 9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 15. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 16. Key Countries Market Analysis 17. Market Structure Analysis 18. Competition Analysis 18.1. Boehringer Ingelheim 18.2. Bristol-Myers Squibb 18.3. FibroGen 18.4. Hoffmann-La Roche Ltd 18.5. Pliant Therapeutics, Inc. 18.6. Galapagos 18.7. Novartis AG 18.8. Prometic Life Sciences Inc. 18.9. Merck & Co., Inc. 19. Assumptions & Acronyms Used 20. Research Methodology
Explore Healthcare Insights
View Reports
Progressive Pulmonary Fibrosis (PPF) Treatment Market
